RNA Vaccine Allergen Encoding Genome Integration Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA-based vaccines for allergic diseases pose safety concerns due to integration risks and potential for uncontrollable anaphylactic reactions, necessitating a safer alternative for preventive vaccination, especially in children.
Innovation Solution
Development of an RNA vaccine comprising RNA molecules encoding allergens, which provides pure genetic information without integrating into the host genome, inducing TH1-biased immune reactions and offering advantages over DNA vaccines by avoiding long-term antigen expression and reducing the risk of anaphylactic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based vaccines are used to prevent allergic diseases, then immune protection can be achieved, but safety concerns arise due to potential integration into host genome and risk of uncontrollable anaphylactic reactions
Solution Approach 1:
The patent extracts the harmful characteristic of DNA vaccines (potential genome integration) by using RNA instead. RNA vaccines deliver genetic information without integrating into the host genome, thereby eliminating the safety concern while maintaining the ability to induce protective immune responses against allergens
Solution Approach 2:
The patent employs RNA molecules that are naturally short-lived and degrade quickly in the cell, unlike DNA which can persist and integrate. This transient nature of RNA ensures that the allergen expression is controlled and limited, preventing sustained anaphylactic reactions while still providing adequate immune protection
2Duration of action of moving object
If DNA vaccines are used to provide sustained allergen delivery, then immune response can be maintained, but uncontrollable anaphylactic reactions may occur in patients with pre-existing IgE molecules
Solution Approach 1:
The patent implements periodic action through the natural degradation cycle of RNA molecules. The RNA is introduced, translated into allergen protein for a limited period to induce immune response, then naturally degrades. This periodic presence of the allergen (introduced then cleared) provides sufficient immune protection without the sustained expression that could trigger uncontrollable anaphylactic reactions
3Reliability
If RNA vaccines are used to avoid genome integration, then safety is improved, but the need for precise control of antigen expression and immune response remains
Solution Approach 1:
The patent applies self-service by utilizing the natural biological degradation pathways of RNA molecules. The RNA vaccine system automatically controls its own duration of action through cellular RNA degradation mechanisms, eliminating the need for complex external control systems. The RNA is introduced, performs its function of inducing immune response, then naturally degrades without requiring additional control mechanisms
Data Source
AI summary
A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba or Phleum pratense.